Trevena Revenue and Competitors

Location

$489.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Trevena's estimated annual revenue is currently $7.5M per year.(i)
  • Trevena's estimated revenue per employee is $187,500
  • Trevena's total funding is $489.6M.

Employee Data

  • Trevena has 40 Employees.(i)
  • Trevena grew their employee count by -20% last year.

Trevena's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP Medical AffairsReveal Email/Phone
3
VP, Medical AffairsReveal Email/Phone
4
VP, Technical OperationsReveal Email/Phone
5
Head Business DevelopmentReveal Email/Phone
6
General Counsel & Chief Compliance OfficerReveal Email/Phone
7
Sr. Director, Head Quality ManagementReveal Email/Phone
8
Associate DirectorReveal Email/Phone
9
SVP and Chief Medical OfficerReveal Email/Phone
10
SVP, Chief Business Officer and Head Commercial OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$4M2613%N/AN/A
#3
$0.9M6-14%N/AN/A
#4
$1.1M70%N/AN/A
#5
$10.9M703%N/AN/A
#6
$0.7M929%N/AN/A
#7
$4M26-16%N/AN/A
#8
$1.7M1122%N/AN/A
#9
$7.6M492%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Trevena?

Approximately 40% of modern medicinal products target GPCRs and GPCRs remain the largest class of targets currently under clinical evaluation. Currently marketed GPCR drugs suffer significant problems such as limited efficacy and undesirable adverse effects, which generally limit their overall use. Furthermore, there are many GPCRs linked to disease that cannot be translated into medicines because of specific target-related adverse effects. Trevena’s novel drug discovery approach combines a powerful, proprietary and efficient drug discovery platform with the Company’s extensive discovery and development experience to yield a rich pipeline of breakthrough medicines. Trevena’s drug discovery technology is based on the groundbreaking research from the laboratories of leading scientists in the field - Robert J. Lefkowitz, M.D. and Howard A. Rockman, M.D. of Duke University Medical Center.

keywords:N/A

$489.6M

Total Funding

40

Number of Employees

$7.5M

Revenue (est)

-20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Trevena News

2022-04-20 - NIH puts the brakes on study of Trevena's experimental Covid-19 ...

Trevena Inc. of Chesterbrook received a notice from the NIH that enrollment in the study ceased after an interim analysis of the study data...

2022-04-17 - UPDATE: Trevena's COVID-19 drug trial halted for inferiority as NIH ...

Enrollment for Trevena's COVID-19 treatment trial, part of the National Institutes of Health's ACTIV-4 program, has ceased after the program's data safety...

2022-03-22 - Trevena Reports Fourth Quarter and Full Year 2021 Results

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.6M408%N/A
#2
$8.6M40-2%N/A
#3
$7.1M42-9%N/A
#4
$10M43-2%N/A
#5
$6.9M43-7%N/A